The development of immunotherapies has transformed the treatment of cancer. Notably, CAR-T and immune checkpoint inhibitors, but extending to various conjugate approaches, monoclonal antibodies and bi-specific technologies, have made the treatment of certain cancers revolutionary.
Yet these therapies are not effective, or durable, for a number individuals, or across various types of cancer. Among the reasons for this is an insufficient cell membrane expression of tumor antigen density. In vitro and ex-vivo cell based studies have demonstrated that bryostatin-1 induces expression of tumor antigen. This approach, initially focused on CD22 expression in pediatric leukemia, will be tested in the clinic in the next 12-15 months. BryoLogyx is collaborating with the NCI in a study to determine the relationship of bryostatin-1 dose to CD22 antigen expression. Once established, there are plans for rapid testing in the clinic using CAR-T with bryostatin-1 produced from the Wender synthetic process.
BryoLogyx will work in collaboration with leading investigators to study a panel of analog compounds, optimized for use, initially in hematologic oncology. If confirmed in clinical trials, bryostatin-1, or its analogs, may be expected to improve the clinical efficacy in both initial treatment, as well as that of relapsed disease.
Additional applications beyond hematologic oncology are being evaluated. Partnership and collaboration with industry, academic and NCI investigators are planned.